Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
5096 studies found for:    "Lymphatic Diseases"
Show Display Options
Rank Status Study
1 Active, not recruiting Tumor Registry of Lymphatic Neoplasia
Condition: Malignant Lymphatic Diseases
Intervention:
2 Recruiting National Lymphatic Disease and Lymphedema Registry
Condition: Lymphedema
Intervention:
3 Completed A Study of Isoprinosine in Patients With Lymph Node Disease
Conditions: Lymphatic Disease;   HIV Infections
Intervention: Drug: Inosine pranobex
4 Completed The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III)
Conditions: Lymphatic Disease;   HIV Infections
Intervention: Drug: Zidovudine
5 Completed The Safety and Effectiveness of Isoprinosine in Patients With Weakened Immune Systems and Lymph Node Disease
Conditions: Lymphatic Disease;   HIV Infections
Intervention: Drug: Inosine pranobex
6 Completed Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome
Conditions: Autoimmune Disease;   Lymphatic Disease;   Lymphoproliferative Disorder
Intervention: Drug: Pyrimethamine
7 Completed A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Immunodepressed Patients With Uncomplicated Generalized Lymphadenopathy
Conditions: Lymphatic Disease;   HIV Infections
Intervention: Drug: Inosine pranobex
8 Recruiting Study of Autoimmune Lymphoproliferative Syndrome (ALPS)
Conditions: Autoimmune Disease;   Lymphatic Disease;   Lymphoproliferative Disorder;   Canale-Smith Syndrome
Intervention:
9 Recruiting Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
Conditions: Lymphatic Diseases;   Hematopoietic Malignancy
Intervention: Biological: Umbilical Cord Blood (UCB)
10 Recruiting Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders
Conditions: Lymphangiomatosis;   Lymphedema;   Lymphangiectasia;   Pulmonary Lymphangiectasia
Intervention:
11 Unknown  Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders
Condition: Lymphedema
Intervention: Drug: near-infrared fluorescence imaging
12 Active, not recruiting Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine- Based Treatment.
Condition: Hodgkin Lymphoma
Interventions: Drug: RAD001;   Drug: Everolimus (RAD001)
13 Active, not recruiting A Phase 1/2 Study of Ponatinib in Japanese Patients With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
Conditions: Chronic Myeloid Leukemia (CML);   Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Interventions: Drug: ponatinib - Phase 1;   Drug: ponatinib - Phase 2
14 Available Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Bone Marrow Failure;   Hemoglobinopathy;   Immune Deficiency;   Osteopetrosis;   Cytopenias;   White Blood Cell Abnormalities;   Red Blood Cell Abnormalities
Intervention: Biological: CD34+ enriched, T Cell Depleted donor stem cell product
15 Completed Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma
Conditions: Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-40
16 Terminated
Has Results
SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma
Condition: Anaplastic Large Cell Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Drug: SGN-30
17 Terminated A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
Conditions: Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Non-Hodgkin
Interventions: Drug: SGN-40;   Drug: placebo;   Drug: rituximab;   Drug: etoposide;   Drug: carboplatin;   Drug: ifosfamide
18 Completed Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL
Conditions: Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Non-Hodgkin
Interventions: Drug: SGN-40;   Drug: rituximab;   Drug: gemcitabine
19 Completed A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: SGN-40 (anti-huCD40 mAb)
20 Active, not recruiting Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Condition: Acute Lymphoblastic Leukemia
Intervention: Drug: Blinatumomab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years